在欧洲,两种CAR-T细胞产品,tisagenlecleucel(Kymriah™)andaxicabtageneciloleucel(Yescarta™),于2018年批准。虽然这些治疗方法可以使用,异基因造血干细胞移植中心仍需要在该领域既定程序的启发下建立专门的护理流程。为了确定必要的资源和行为者,必须提前计划CART细胞护理过程的每个步骤.这个过程,由中心的协调护士实施,应该能够适应每个中心的需求。该研讨会的目的是为这种过程提供组织基础,以便希望建立CAR-T细胞活性的每个中心都可以有效地做到这一点。在详细说明了协调护士的角色之后,我们解释护理过程的每个步骤,并指定必要的额外测试。
In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. While these treatments are available for use, allogeneic hematopoietic stem cell transplantation centers still need to set up a dedicated care process inspired by established procedures in the field. In order to determine necessary resources and actors, each step of the CAR T-cell care process must be planned in advance. This process, implemented by the center\'s coordinating nurse, should be able to be adapted to each center\'s needs. The purpose of this workshop is to provide the organizational basis for such a process so that each center wishing to set up CAR-T cell activity can do so effectively. After detailing the coordinating nurse\'s role, we explain each step of the care process and specify essential additional tests.